Record Q3 Total Revenues and Enterprise Cloud Bookings Announces $250 Million Share Repurchase Program Fiscal 2024 Third Quarter Highlights Annual Recurring Revenues represent 79% of Total Revenues Total revenues of $1.447 billion, up 16.3% Y/Y or up 16.0% in constant currency (CC)Annual Recurring Revenues (ARR) of $1.146 billion, up 13.3% Y/Y or up 13.1% in CCCloud revenues of $455 million, up 4.4% Y/Y and up 4.4% in CCQuarterly enterprise cloud bookings(1) of $165 million, up 52.6% Y/YOperating cash flows of $385 million, up 14.2% Y/YFree cash flows(2) of $348 million, up 13.9% Y/YGAAP-based net income of $98 millionAdjusted EBITDA(2) of ...

WINNIPEG, MB, le 3 mai 2024 /CNW/ - La Société financière IGM Inc. (IGM) (TSX: IGM) a annoncé aujourd'hui ses résultats au titre du total de l'actif géré et de l'actif sous services-conseils, qui s'élevait à 246,7 milliards de dollars au 30 avril 2024, comparativement à 252,2 milliards au 31 mars 2024 et à 236,5 milliards au 30 avril 20231. Le total des sorties nettes consolidées s'établissait à 253 millions de dollars en avril 2024.

Management Circular and Proxy Materials Now Available TORONTO, May 2, 2024 /CNW/ - RF Capital Group Inc. (the Company) (TSX: RCG) announced today it will hold its annual meeting of shareholders (the Meeting), in person, at the Toronto Region Board of Trade, on Tuesday, June 4, at 1:30 p.m. (EST). The Chair of RF Capital's Board of Directors, Donald Wright, will host the Meeting. President and CEO, Kish Kapoor, will then discuss the financial and strategic highlights of 2023, and provide an update on the Company's progress against its three-pillar strategy.  A slide presentation and live webcast will be accessible at ...

--Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis Clinical Program--  VICTORIA, BC, May 2, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano and Dr. Roos Pouw. The Clinical Advisory Board will work closely with Eupraxia as it continues ...